RxDoctor Payments Data

Christie Gannon

Family · El Dorado, KSNPI 1487361416

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 45 payments — averaging $27.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$575
  • Bayer$275
  • Novo Nordisk$125
  • GSK$81
  • Lilly USA, LLC$75
  • Sumitomo Pharma America, Inc.$24
  • plus $98 from 5 others

What the payments were for

  • Food & beverage$1,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,253 in reported general payments places this provider in the 75th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$16,958
Medicare patients
74
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$41,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,979
FarxigaDapagliflozin Propanediol19$13,654
Synjardy XrEmpagliflozin/Metformin Hcl15$12,484
TrulicityDulaglutide12$11,805
JardianceEmpagliflozin16$9,869
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,518
Varenicline Tartrate20$5,953
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,919
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen63$2,409
Pregabalin67$2,324
Celecoxib39$2,304
Albuterol Sulfate HfaAlbuterol Sulfate62$1,439
Gabapentin56$984
Cefdinir38$803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$75$52,92050 claims
AstraZenecaFarxiga, Breztri Aerosphere$575$23,17232 claims
GSKTrelegy Ellipta$81$15,97923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,579 family providers in Kansas.

Other family in El Dorado

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →